**Hepatology COVID-19 Registry**  
**Week 12 Report**  
2 new cases added to the report since last week

<table>
<thead>
<tr>
<th></th>
<th>Liver disease, Non-Transplant (N=23)</th>
<th>Post-liver transplantation (N=22)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Gender (%)</strong></td>
<td>Female = 10 (43.47%) Male = 13 (56.53%)</td>
<td>Female = 10 (45.45 %) Male = 12 (54.54 %)</td>
</tr>
<tr>
<td><strong>Median Age (yr) at time of COVID diagnosis (range)</strong></td>
<td>5 (0.16-20)</td>
<td>13.5 (0.5-21)</td>
</tr>
</tbody>
</table>
| **Etiology of liver disease** | Biliary atresia = 7  
NAFLD = 5  
Autoimmune hepatitis = 5  
Metabolic disorder = 1  
Acute Liver Failure = 1  
Others* = 4 | Biliary atresia = 8  
Acute liver failure = 6  
Metabolic disorders = 2  
Tumor = 2  
Others** = 4 |
| **Highest level of care** | | |
| Outpatient               | 7                                      | 16                                  |
| Hospital floor           | 9                                      | 3                                   |
| ICU                      | 7                                      | 3                                   |
| **Immunosuppression at time of COVID diagnosis** | No Immunosuppression = 18  
Azathioprine = 5  
Steroids =3 | Tacrolimus = 18  
Steroids = 9  
Mycophenolate Mofetil = 8  
Sirolimus = 3  
Azathioprine = 1  
Cyclosporine =1 |
| **Specific Treatment for COVID** | Hydroxychloroquine + Azithromycin = 3  
IVIG = 4  
Steroids = 3  
Remdesivir = 2  
Tocilizumab + Sarilumab = 1  
Rocilizumab Sarilumab = 1  
Convalescent Plasma = 1  
Anakinra = 1  
Eculizimab = 1 | Hydroxychloroquine = 2  
Azithromycin = 1  
IVIG = 1  
 Favipiravir = 1 |
| **Highest respiratory support** | | |
| None                     | 16                                     | 18                                  |
| Nasal cannula/CPAP/BiPAP | 3                                      | 2                                   |
| Mechanical ventilation   | 3                                      | 0                                   |
| High Frequency Oscillatory ventilation | 1 | 0 |
| Pending information      | -                                      | 2                                   |
| **Final clinical outcome** | | |
| Death                    | 1***                                   | 0                                   |
| Recovery                 | 20                                     | 17                                  |
| Still active in clinical course | 2 | 2 |
| Pending information      | -                                      | 3                                   |
| **Liver related Complications** | Ascites = 6  
Portal Hypertension Bleeding =1  
Infection = 1 | - |

*Others CLD: idiopathic cholestasis, GVHD/vanishing bile duct syndrome (Post BMT), IFALD with biliary obstruction, PFIC  
** Others PLT: IFALD, Congenital hepatic fibrosis, AIH-Sclerosing cholangitis  
***Pulmonary hemorrhage, multi-organ failure  
Two recipients had multivisceral transplantation; One PLT recipient also had a transplanted kidney.
Presenting symptoms at time of diagnosis

*Constitutional symptoms reported: Loss of smell/taste, fever, myalgia, fatigue, sore throat
# Other symptoms reported: Malaise, anorexia, headache, rash, Kawasaki disease like presentation (MIS-C)

Change done to Immunosuppressive agent (Post LT)

*Stopped, decreased the dose, others and No changes
Commonest agent stopped: Mycophenolate Mofetil